<DOC>
	<DOCNO>NCT00761306</DOCNO>
	<brief_summary>The purpose study evaluate long-term safety tolerability Vortioxetine period 52 week patient Major Depressive Disorder ( MDD ) complete 6-week acute treatment study NCT00839423 / 11492A .</brief_summary>
	<brief_title>Open-label Safety Extension Study 5 10 mg Vortioxetine ( Lu AA21004 ) Long-term Treatment Major Depressive Disorder Adults</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder , Major</mesh_term>
	<mesh_term>Vortioxetine</mesh_term>
	<criteria>Patients complete 6week shortterm treatment study Major Depressive Episode ( MDE ) , NCT00839423 / 11492A , follow 2week taper period Any current psychiatric disorder MDD define Diagnostic Statistical Manual Mental Disorders , 4th Edition , Text Revision ( DSMIV TR ) Female patient childbearing potential use effective contraception Use psychoactive medication Other protocoldefined inclusion exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2013</verification_date>
	<keyword>Major Depressive Disorder</keyword>
	<keyword>Long-term</keyword>
	<keyword>Safety</keyword>
	<keyword>Open-label</keyword>
</DOC>